Stem Cell Therapy in Progressive Liver Fibrosis: Una revisione completa

Liver fibrosis is a chronic condition characterized by the excessive accumulation of scar tissue in the liver, leading to impaired liver function and potentially life-threatening complications. Stem cell therapy has emerged as a promising approach for treating liver fibrosis by harnessing the regenerative potential of stem cells. This review provides a comprehensive overview of the current understanding of stem cell therapy in progressive liver fibrosis.

Etiology and Pathogenesis of Liver Fibrosis

Liver fibrosis is primarily caused by chronic liver injury, which can result from various etiologies such as viral infections, abuso di alcol, steatosi epatica non alcolica, e disturbi autoimmuni. Hepatic stellate cells (HSC) are the primary mediators of fibrosis. Upon activation, HSCs undergo a phenotypic transformation into myofibroblasts, which produce and secrete excessive extracellular matrix (ECM) componenti, leading to the formation of fibrotic scars.

Ruolo delle cellule staminali nella rigenerazione del fegato

Le cellule staminali possiedono la capacità di autorinnovarsi e differenziarsi in vari tipi cellulari. Nel fegato, stem cells contribute to liver regeneration and repair. Two main types of stem cells involved in liver regeneration are mesenchymal stem cells (MSC) and hepatic stem cells (HSC). MSCs can differentiate into hepatocytes, cholangiocytes, and other liver cell types, while HSCs give rise to hepatocytes.

Mesenchymal Stem Cells for Fibrosis Treatment

MSCs have shown promise in treating liver fibrosis. They can inhibit HSC activation and proliferation, promote hepatocyte regeneration, e modulare la risposta immunitaria. Preclinical studies have demonstrated that MSCs can reduce fibrosis and improve liver function in animal models of liver disease. Clinical trials are currently underway to evaluate the safety and efficacy of MSC therapy in patients with liver fibrosis.

Nota informativa:
Le informazioni contenute in questa pagina sono destinate a scopi scientifici, educativo, e scopi informativi generali. Approcci clinici, disponibilità, e lo stato normativo può variare in base al Paese, istituzione, e indicazione medica. Per decisioni mediche individuali, i lettori dovrebbero consultare operatori sanitari qualificati e centri medici accreditati.
Nota editoriale:
Questo articolo è stato preparato dal team editoriale di NBScience nell'ambito della ricerca clinica, biotecnologia, e informazioni mediche internazionali.
Categorie: Colpo Attacco ischemico transitorioTrattamento con cellule staminaliCellule staminali in EuropaIl mercato delle cellule staminaliricerca sulle cellule staminaliterapie con cellule staminaliTerapia con cellule staminaliTerapia con cellule staminali & Ricerca clinicacellule staminaliterapia con cellule staminali

NBScienza

organizzazione di ricerca a contratto

Whatsapp